NIH RAC REVIEW GROUP SUGGESTS GENE THERAPY CANCER PROTOCOLS MAY NEED TO EVALUATE TUMOR REDUCTION AS WELL AS TOXICITY IN MODIFIED PHASE I TRIALS
Executive Summary
Gene therapy cancer protocols being reviewed by the National Institute's of Health Recombinant DNA Advisory Committee may need to assess tumor reduction as well as toxicity, members of the ad hoc review committee to RAC asserted at their first meeting Feb. 3.